DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Last trade$173.69
Day change-$0.53 (-0.30%)
Day range$172.97 – $176.67
Volume204,145
Market cap$10.96B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.96B
Price / earnings
11.91×
Price / book
-18.54×
Price / sales
0.8×
EV / sales
1.55×
EV / EBITDA
9.05×
Profitability
Earnings per share
$14.63
Return on assets
5.16%
Return on equity
-155.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-18.22×
Current ratio
1.41×
Quick ratio
1.36×
Cash ratio
0.17×
Cash flow
Price / cash flow
5.86×
Price / free cash flow
8.47×
Free cash flow
$1.29B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DVA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.41B
$3.37B
$3.27B
$3.62B
$3.3B
$3.21B
$3.1B
$3.29B
Cost of revenue
$2.45B
$2.39B
$2.34B
$2.41B
$2.33B
$2.26B
$2.24B
$2.23B
Gross profit
$957.22M
$974.38M
$930.54M
$1.21B
$965.33M
$945.33M
$863.33M
$1.07B
Selling, general and administrative
$408.7M
$423.46M
$421.91M
$472.36M
$414.37M
$412.81M
$374.09M
$414.48M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$636.06M
$591.27M
$599.74M
$659.07M
$591.86M
$587.51M
$550.54M
$623.73M
Operating income
$321.16M
$383.11M
$330.8M
$551.21M
$373.47M
$357.82M
$312.79M
$445.58M
Interest expense
-$150.02M
-$150.26M
-$145.13M
-$148.25M
-$150.56M
-$146.06M
-$135.06M
-$138.72M
Income before taxes
$358.71M
$435.01M
$341.23M
$382.76M
$308.8M
$368.93M
$286.33M
$413.73M
Income taxes
$89.32M
$91.79M
$66.2M
$76.73M
$68.55M
$93.71M
$54.12M
$64.49M
Net income
$269.39M
$343.22M
$275.04M
$331.03M
$240.25M
$275.22M
$232.22M
$349.25M
Net income attributable to common shareholders
$222.93M
$265.4M
$197.53M
$234.22M
$150.33M
$199.34M
$162.92M
$259.33M
EBITDA
$548.52M
$550.92M
$508.63M
$737.91M
$550.96M
$532.53M
$489.24M
$619.68M
Basic earnings per share
$3.49
$4.10
$2.93
$3.37
$2.09
$2.62
$2.05
$3.18
Diluted earnings per share
$3.40
$4.02
$2.87
$3.29
$2.04
$2.58
$2.00
$3.09
Recent news
Company coverage with links to the original publishers.
Law firm Lowey Dannenberg is investigating DaVita Inc. for potential securities law violations following the HHS announcement of a coordinated strategy to revitalize American kidney care by introducing competition measures and penalizing market dominance in the dialysis industry. DaVita's stock fell 6.23% ($11.65 per share) on October 20, 2026, following the announcement, as investors question whether the company adequately disclosed regulatory and competitive risks.
Zacks recommends three AllianceBernstein mutual funds for long-term investors: AB High Income (AGDAX), AB All Market Real Return (AMTAX), and Bernstein International Small Cap (IRCSX). All three funds hold Zacks Mutual Fund Rank #1 (Strong Buy), feature positive three and five-year annualized returns, and maintain expense ratios below category averages.
DaVita (DVA) reported Q3 2026 adjusted EPS of $3.82, up 52.2% YoY, and revenues of $3.58 billion, up 4.6%, beating consensus estimates. Strong performance in Integrated Kidney Care and international operations drove results, though higher patient care costs and sequential RPT decline pressured margins. The company narrowed 2026 EPS guidance to $14.30-$15.20 amid cost pressures.
DaVita is expected to report Q3 2026 results on October 29 with EPS projected to rise 50.6% YoY to $3.78 and revenues growing 3.2% to $3.53B. Improving treatment volumes and favorable calendar effects should support growth, while cost controls and kidney care gains may offset reimbursement pressures. However, weak commercial payor mix and revenue per treatment pressures remain concerns.
DaVita HealthCare fell 1.32% on October 23, 2026, underperforming the S&P 500's 0.52% decline. Despite the daily drop, DVA has gained 6.54% over the past month, outpacing the Medical sector's 3.23% gain. The company is expected to report earnings on October 29 with projected EPS of $3.78 (up 50.60% YoY) and revenue of $3.53 billion (up 3.23% YoY). DVA trades at a Forward P/E of 12.77, below the industry average of 20.58, and holds a Zacks Rank of #3 (Hold).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.